The lymphocyte toxicity assay (LTA) is a proposed surrogate marker of sulfonamide antibiotic hypersensitivity. In the LTA, peripheral blood mononuclear cells (PBMCs) undergo apoptosis more readily in hypersensitive versus tolerant patients when exposed to drug-hydroxylamine metabolites in vitro. The purpose of this study was to identify key gene transcripts associated with increased cytotoxicity from sulfamethoxazole-hydroxylamine in human PBMCs in the LTA. The LTA was performed on PBMCs of 10 patients hypersensitive to trimethoprim-sulfamethoxazole (HS) and 10 drug-tolerant controls (TOL), using two cytotoxicity assays: and MTT (n = 12). mRNA expression profiles of PBMCs, enriched for CD8 + T cells, were compared between HS and TOL patients. Transcript expression was interrogated for correlation with % cytotoxicity from YO-PRO and MTT assays. Correlated transcripts of interest were validated by qPCR. LTA results were not significantly different between HS and TOL patients, and no transcripts were found to be differentially expressed between the two groups. 96 transcripts were correlated with cytotoxicity by YO-PRO (r = AE.63-.75, FDR 0.188). Transcripts were selected for validation based on mechanistic plausibility and three were significantly overexpressed by qPCR in high cytotoxicity patients: multi-specific organic anion transporter C (ABCC5), mitoferrin-1 (SLC25A37), and Porimin (TMEM123). These data identify novel transcripts that could contribute to sulfonamide-hydroxylamine induced cytotoxicity. These include SLC25A37, encoding a mitochondrial iron transporter, ABCC5, encoding an arylamine drug transporter, and TMEM123, encoding a transmembrane protein that mediates cell death.
| INTRODUCTION
Sulfonamide antibiotics, such as sulfamethoxazole (SMX) in combination with trimethoprim (TMP), are indicated for the treatment of urinary and respiratory tract infections and skin infections caused by methicillinresistant Staphylococcus aureus.
1-4 TMP-SMX is also the drug of choice for the prevention and treatment of opportunistic fungal infections in immunocompromised patients, including those with AIDS. [5] [6] [7] [8] Unfortunately, sulfonamide antibiotics, including potentiated sulfonamides as part of a folate synthesis combination, can cause idiosyncratic drug toxicity, also called sulfonamide hypersensitivity (HS), 9 which is characterized by delayed onset of fever and pruritic skin rash after 5-14 days of treatment. Less commonly, HS can progress to multiorgan involvement or severe bullous skin eruptions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, with up to 30% mortality. 10, 11 Sulfonamide HS occurs in both immunocompromised and immunocompetent populations with incidence rates of 20%-57% in HIV-infected patients and~3% in the general population. [12] [13] [14] [15] [16] In the former, the risk for this drug reaction appears to be acquired and is associated with advancing disease status. 14, [17] [18] [19] In contrast, there is some evidence that sulfonamide HS in immunocompetent patients has a familial component, [20] [21] [22] suggesting a genetic association.
A few polymorphic candidate genes have been investigated for associations with sulfonamide HS and focus predominantly on those involved with SMX biotransformation and detoxification. Genotypes for N-acetyltransferase (NAT2), the primary SMX detoxification enzyme, have been associated previously with sulfonamide HS, 23, 24 but in a larger, more recent study in our laboratory, we found no associations with HS despite resequencing of the entire NAT2 coding region. 25 In that same population, polymorphism frequencies for two other sulfonamide detoxification genes, CYB5A and CYB5R3, were not significantly different between sulfonamide HS and tolerant patients. 25 In another study, an increased risk for cutaneous drug eruptions overall was reported for patients with GSTM1 and GSTT1 null genotypes, but only 4 of 36 patients studied were hypersensitive to sulfonamide antibiotics. 26 An association between sulfonamide-induced skin eruptions and an HLA-A haplotype (A30 B13 Cw6) was found in a Turkish population, 27 but this has not been pursued in other ethnic groups. Finally, our group recently performed a genome-wide association study in immunocompetent individuals, but did not identify any convincing genetic associations with sulfonamide HS, 28 emphasizing the complex nature of this trait. Therefore, alternate approaches are needed to understand the mechanisms of risk for sulfonamide HS in the general population.
In both immunocompetent and HIV-infected patients, sulfonamide HS has been associated with a surrogate marker identified by the lymphocyte toxicity assay (LTA). Results of this in vitro cytotoxicity assay
show that peripheral blood mononuclear cells (PBMCs) from HS patients are more susceptible to apoptosis in the presence of sulfonamide metabolites, particularly SMX-hydroxylamine (SMX-HA), when compared to cells from sulfonamide-tolerant patients. Interestingly, this enhanced cytotoxicity does not occur when cells are exposed to the parent drug (SMX) emphasizing the importance of drug bioactivation in the hypersensitivity reaction. [29] [30] [31] [32] Furthermore, CD8 + T cells appear to be most susceptible to the LTA response, possibly due to lower intracellular antioxidant concentrations. 33 The significance of this finding is unknown; however, T cells are the major effector cells in delayed-type hypersensitivities. 34 Cytotoxicity in the LTA has been measured by multiple methods, including trypan dye exclusion, 22, 35 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) conversion, 29, 31, 32, [36] [37] [38] and YO-PRO fluorescence. 39 These findings have been interpreted as a "detoxification defect" in HS but not tolerant patients. 30, 40, 41 Furthermore, this apparent defect occurs in family members of HS patients who have never received potentiated sulfonamides, 21, 22, 41 which suggests a heritable component.
However, the mechanism for this possible defect is not understood.
Therefore, the purpose of this study was to identify key gene transcripts and pathways that are associated with increased cytotoxicity in the LTA in patients treated with potentiated sulfonamides.
| MATERIALS AND METHODS

| Subject recruitment
Patients with sulfonamide HS and controls tolerant of a course of potentiated sulfonamide antibiotics were identified in the electronic medical record and recruited through UW Health. Additional patients and controls were recruited among the UW-Madison faculty, staff, and students. Medical records were searched electronically for a history of TMP-SMX administration or for a diagnosis of sulfonamide HS, and then were reviewed using a structured abstraction form. The abstraction form included the following eligibility criteria: (1) administration of TMP-SMX for at least 5 days prior to the adverse event 9 ; (2) For a subset of samples where cell volumes were adequate, % cytotoxicity was also determined using the MTT detection method.
After incubation of PBMC with SMX-HA, SMX, or drug vehicle, and overnight incubation without drug as for the YO-PRO assay, 10 lL of 12 nmolÁL À1 MTT was added to each well and incubated at 37°C
for 4 hours to allow generation of formazan. 37 The formazan was solubilized with 100 lL 0.1 N HCl in isopropyl alcohol and absorbance measured at 570 nm. For each condition, % cell viability was defined as absorbance for drug-exposed cells divided by the absorbance of cells treated with drug vehicle; % cytotoxicity was then calculated as 100% minus % viability. To each tube, 200 lL chloroform was added, shaken, and centrifuged at 16 100 g at 4°C for 5 minutes. The aqueous phase was transferred to a clean tube and 500 lL ice-cold 100% isopropanol added. RNA was precipitated for 1 hour at À20°C. Tubes were centrifuged at 16 100 g at 4°C for 10 minutes, supernatant removed, and the pellet allowed to dry completely. RNA was then resuspended in nuclease free water. Genomic DNA contaminants were digested using TURBO DNA-free (ThermoFisher Scientific; Madison, WI) and residual extraction reagents removed using RNeasy MinElute Cleanup (Qiagen; Hilden, Germany) according to manufacturers' directions.
| RNA isolation and expression microarray of CD8 + T cell-enriched PBMCs
Prior to expression profiling, RNA quality was assessed on the Agilent 2100 Bioanalyzer (RNA 6000 Pico Kit; Agilent Technologies; Santa Clara, CA); samples with an RNA Integrity Number ≥8 were used for expression arrays. 46 Microarray expression profiling was performed using the Human Transcriptome Array 2.0 (Affymetrix; Santa Clara, CA) on the Affymetrix GeneChip platform through the University of Wisconsin Biotechnology Center. The gene expression data were extracted using RMA-Sketch in the Affymetrix Expression Console (version 1.14.46), and the exon data were extracted using Alt Splice Analysis in the Affymetrix Expression Console (version 1.14.46).
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| Validation of transcript expression with quantitative PCR (qPCR)
Expression levels of genes of interest identified by the microarray to be associated with % cytotoxicity were verified with qPCR. Reverse transcription with random oligomers (Superscript IV VILO cDNA Synthesis Kit; ThermoFisher Scientific; Madison, WI) was used to generate cDNA.
Primers were designed for the target gene transcripts along with two reference genes (GUSB, HPRT1) and primer efficiencies determined for each using a 10-fold dilution series of pooled cDNA (Table S1) Three separate analyses were performed on gene-level scores.
The first assessed differential expression based on clinical status (TOL vs HS patients) using gene-specific t tests. The second and third analyses assessed the correlation between gene expression and % cytotoxicity as determined by the YO-PRO and MTT methods, respectively, using Fisher's z-transformation. In all analyses, independent filtering 47 was used to remove the 50% of genes with the lowest variance, in an effort to increase power, and false discovery rates were computed using the Benjamini-Hochberg adjustment after filtering. 48 Of the genes assessed, candidate genes previously hypothesized to be involved in sulfonamide HS pathogenesis ( 3 | RESULTS
| Patient population
Ten HS and 10 TOL patients were included in this study. Patient demographics are summarized in Table 2 . Sulfonamide HS was characterized by cutaneous rash in all 10 HS patients, and one patient had a documented fever.
| Lymphocyte toxicity assays
The Lymphocyte toxicity assays (LTA) with YO-PRO detection was Table S3 ). No a priori candidate genes were among these transcripts.
Of interest, expression of ABCC5, which encodes an organic anion pump and is known to transport arylamine-containing drugs including methotrexate and leucovorin, 50 was negatively correlated with YO-PRO cytotoxicity (r = À.70). Expression of SLC25A37, which encodes a mitochondrial iron transporter, was also negatively correlated with YO-PRO cytotoxicity (r = À.71). TMEM123, which encodes Porimin, a transmembrane cell protein associated with cell death, was positively correlated with YO-PRO cytotoxicity (r = .72).
Microarray data from this study are available in the GEO database (www.ncbi.nlm.nih.gov/geo; accession number GSE100443).
Seven Gene Ontology (GO) terms were identified in the pathway analysis that contained more than one correlated transcript (Figure 3) . Of interest, a group of eight ribosomal protein genes (RPL13, RPL21, RPL24, RPL37, RPL38, RPL9, RPS11, RPS29) was identified in four of the seven GO terms. All eight of these genes were positively correlated with cytotoxicity.
Transcripts were selected for validation by qPCR based on strength of correlation and mechanistic plausibility with SMX-HAinduced cytotoxicity (Table S1 ), including ABCC5, SLC25A37 because of the relationship between mitochondrial function and cell survival,
TMEM123
, and RPL37, which encodes ribosomal protein, large subunit 37, and was selected to represent the group of ribosomal proteins identified in the pathway analysis. The inverse correlation between ABCC5 expression and cytotoxicity in the array was confirmed by qPCR (r = À.49, P = .02; Figure 4 ). The negative correlation between SLC25A37 expression and % cytotoxicity approached statistical significance by qPCR (r = À.42, P = .067); when an extreme outlier (>3 SD above the mean) was removed the correlation (r = À.63, P = .0037; Figure 5 ) was comparable to that found in the array. The positive correlation between TMEM123 expression and cytotoxicity was also confirmed by qPCR (r = .53, P = .017; Figure 6 ). For RPL37 a weaker positive correlation was found between % cytotoxicity and RPL37 expression by qPCR that did not reach statistical significance (r = .32, P = .17; Figure 7 ).
Using MTT cytotoxicity as the outcome, no transcripts were significantly correlated with % cytotoxicity when using independent filtering. However, without independent filtering, a correlation was found for a single transcript, TMEM129, which encodes a transmembrane protein that mediates cellular protein degradation (r = .92, with FDR <0.05). TMEM129 expression was also assessed by qPCR, but an association with % cytotoxicity could not be confirmed (r = .40, P = .19), possibly due to low power in just 12 patients.
T A B L E 2 Demographic information for drug-tolerant (TOL) and sulfonamide hypersensitive (HS) patients. Continuous data are presented as mean (range)
TOL (n = 10) HS (n = 10) 
| DISCUSSION
The lymphocyte toxicity assay (LTA) has been proposed as an in vitro marker of sulfonamide HS. 30, 40, 41 However, the mechanism underlying enhanced cytotoxicity of PBMCs to reactive SMX metabolites is not established. Therefore, we set out to define differences in gene expression between patients with high versus low susceptibility to SMX-HA cytotoxicity in vitro, using two methods for evaluation of cytotoxicity. We chose YO-PRO-1 as our primary method, which is a DNA-intercalating fluorophore that measures increased cell permeability is a marker of cellular apoptosis and death. 51 We also used the classical MTT assay, which measures mitochondrial viability, in a subset of patients with adequate PBMCs for both assays. 52 In our hands, there was poor correlation between cytotoxicity from SMX-HA using the YO-PRO versus MTT assay across patients.
Part of this may due to small sample size. Additionally, we had inadequate PBMC numbers to perform the MTT assay on all patients.
However, the lack of correlation could also be due to different assay outcomes (cell permeability versus mitochondrial function) and both assays have diagnostic weaknesses. As a vital dye, YO-PRO is considered a conclusive test for cell death. 53 However, false negatives can occur with cell death that does not involve increased membrane permeability 53 and false positives are possible with high expression of transporters for large cations. 54 In the MTT assay, impaired mitochondrial reductase function in otherwise healthy cells will yield falsely low viability results. 53 These factors may lead to discordant results between YO-PRO and MTT assays. 55 We used cytotoxicity of SMX-HA at 800 lM for statistical com- patients at this concentration for either method, which was a concern given the results of previous studies. 22, 32, 56 The reported specificity of the LTA is quite high (78%-99%), but sensitivity varies greatly (41%-100%). 36, 41, 56, 57 In the relatively small numbers of patients recruited for expression arrays in our study, the lack of sensitivity reported by some groups could have led to poor discrimination between HA and TOL patients. Additionally, the performance of the LTA in drug HS appears to vary with the severity of clinical presentation. In patients with only an exanthemous rash, sensitivity is quite low (41%), but is much higher in patients with more serious systemic organ involvement (92%). 56 Although patients with Stevens-Johnson syndrome and toxic epidermal necrolysis were not excluded from this study, 9/10 patients in our population only exhibited a cutaneous rash and 1/10 exhibited a rash and fever. Thus it is possible that the LTA would have performed better if only patients with severe reactions were included. Alternately, these differences in apparent assay sensitivity may reflect problems not with the assay but with accurate phenotyping of patients with simple rash, which can have causes other than drug HS.
Although we did not find differences in cytotoxicity outcomes by clinical phenotype in our population, we were still interested in underlying gene expression patterns associated with the wide range of SMX-HA cytotoxicities that we did observe. After independent filtering, which removes transcripts with low variance between samples, expression levels for 96 transcripts were significantly correlated with SMX-HA cytotoxicity using the YO-PRO method. These genes represent a wide range of cellular localization and functions, but none were a priori candidate genes known or hypothesized to metabolize sulfonamide antibiotics ( SLC25A37 encodes mitoferrin 1, a solute carrier in the inner mitochondrial membrane that is known to transport iron. SLC25A37
expression was inversely correlated with SMX-HA induced cytotoxicity in the microarray, and was confirmed with qPCR. SLC25A37 has been most studied relative to heme biosynthesis in erythroid cells, but its role in nonerythroid cells is not well-characterized. 62 Downregulation of mitoferrin 1 in lymphoid cells could plausibly lead to iron-induced redox stress, and possible increased susceptibility to reactive xenobiotics such as SMX-HA. Of note, SLC25A28, which encodes for mitoferrin 2, another mitochondrial iron transporter highly homologous to mitoferrin 1, 63 was also inversely correlated with % cytotoxicity in the microarray (r = À.66, Table S3 ).
TMEM123, which encodes Porimin, was positively correlated with % cytotoxicity by YO-PRO detection in the microarray and by qPCR. Porimin has been shown to increase membrane permeability and cell death in Jurkat (lymphoid) cells. 64 This has direct relevance for the cytotoxicity observed in the in vitro LTA, but could also influence susceptibility to sulfonamide HS in vivo through increased cell death from relatively lower concentrations of reactive SMX metabolites, and enhanced "danger signals" to trigger a systemic immune response to cellular drug adducts. 65 Like ABCC5, TMEM123 deserves further study relative to the risk of sulfonamide HS.
RPL37 was one of a group of 8 ribosomal proteins that were significantly and positively correlated with SMX-HA cytotoxicity by YO-PRO (r = .63-.68). While this correlation could not be confirmed by qPCR (r = .32, P = .17), agreement between these two methodologies is affected by multiple factors and lack of concordance 66 does not necessarily invalidate microarray results. Although there is not a clear mechanistic relationship between upregulation of ribosomal proteins (which was assessed in an aliquot of PBMC that were not exposed to drug metabolite in vitro) and increased drug cytotoxicity, RPL37 overexpression has been shown to lead to increased cell death in vitro. 67 Thus, the effects of up-regulation of this and related genes on drug-induced cytotoxicity deserved further study.
The major limitation of this study was its small sample size, which was limited in part by the expense of expression array analyses and by the logistics of prospective recruitment and adjudication of patients for fresh sample collection from a single hospital. We also only included patients with a well-documented reaction, drug exposure, and history, further limiting the patient recruitment pool.
However, our sample size was based on an a priori power calculation that 10 patients per group would provide 80% power to detect 2.5-fold or greater differences in transcript expression. 68 Thus, it is possible that there are differences in gene expression between HS and TOL patients that were not detectable by the current study design.
We also used a lenient false positive discovery rate to detect novel transcripts that might lead to new mechanistic insights.
Another potential limitation of the study was the use of CD8 + enriched, but not pure, lymphocytes. While the LTA is traditionally performed on mixed PBMC, a previous study demonstrated that CD8 + T lymphocytes were the predominant cell type affected by SMX-HA cytotoxicity. 33 We chose to focus on the cell type with the highest toxicity phenotype for expression arrays, with the goal of providing a more homogenous background with less noise from different cell types. Negative selection for enrichment of CD8 + T cells provided adequate RNA for robust array analyses, but since cell yields were not pure, our results may have been clouded by expression patterns in other mononuclear leukocytes in the samples. Finally, certain clinical data, which could be of interest or introduce bias (severity of rash, brand of sulfonamide antibiotic), were not available for analysis.
In summary, although high SMX-HA cytotoxicity toward patient PBMC has been previously attributed to a possible innate defect in drug detoxification, 30, 40, 41 we found no evidence for an association between increased cytotoxicity and altered expression of genes known or hypothesized to be involved in sulfamethoxazole biotransformation. Instead, expression array analyses suggested other novel pathways that could contribute mechanistically to SMX-HA cytotoxicity, and by extension, to sulfonamide HS in some populations.
Novel genes of particular interest include ABCC5, which encodes an arylamine drug transporter, and TMEM123, which encodes a transmembrane protein that mediates cell death. ABCC5 in particular is polymorphic, 58 and additional work is needed to determine whether this transporter mediates SMX or SMX-HA efflux from cells, and whether this is affected by known ABCC5 polymorphisms.
